Determining the feasibility of objective adherence measurement with blister packaging smart technology
| Autor: | Willem W. Verberk, Hein A W van Onzenoort, Cees Neef, Peter W. de Leeuw, Paul-Hugo M. van der Kuy, H. Peter van Iperen |
|---|---|
| Přispěvatelé: | Farmacologie en Toxicologie, Interne Geneeskunde, Family Medicine, RS: CARIM School for Cardiovascular Diseases, RS: MHeNs School for Mental Health and Neuroscience |
| Rok vydání: | 2012 |
| Předmět: |
Technology
Patients Tetrazoles Medication adherence Pharmacy Invasive mycoses and compromised host [N4i 2] Therapy compliance Pharmacy community Blister pack Humans Technology Pharmaceutical Medicine skin and connective tissue diseases Drug Packaging Drug Labeling Netherlands Pharmacies Pharmacology Community pharmacies integumentary system business.industry Health Policy Reproducibility of Results Valine Hypotensive agents Equipment Design Patient counseling Smart technology medicine.disease Clinical Practice Packaging Feasibility Studies Patient Compliance community Valsartan Medical emergency Drug Monitoring Once daily business Angiotensin II Type 1 Receptor Blockers Compliance Pharmaceutical services |
| Zdroj: | American Journal of Health-System Pharmacy, 69, 872-9 American Journal of Health-System Pharmacy, 69, 10, pp. 872-9 American Journal of Health-System Pharmacy, 69(10), 872-879. American Society of Health-Systems Pharmacy |
| ISSN: | 1535-2900 1079-2082 |
| Popis: | Item does not contain fulltext PURPOSE: The results of a feasibility study of blister-pack smart technology for monitoring medication adherence are reported. METHODS: Research in the area of objective therapy compliance measurement has led to the development of microprocessor-driven systems that record the time a unit dose is removed from blister packaging. One device under development is the Smart Blister-a label imprinted with event-detection circuitry that can be affixed to standard commercial blister cards. In the first trial of the device in actual clinical practice, 115 community-dwelling Dutch patients receiving valsartan maintenance therapy (160 mg once daily) were given 14-day blister packages equipped with the Smart Blister. On the return of empty blister cards to the 20 participating community pharmacies, the stored information was scanned and downloaded for data analysis and patient counseling purposes. RESULTS: A total of 245 Smart Blister-equipped packages were used by valsartan recipients during the eight-month study. The device was largely effective in recording patient and blister-card identification data and other desired information. However, in 17% of cases, the Smart Blister system registered multiple tablet-removal events at the same time, presumably indicating unintentional breakage of nearby conductive circuits and the need for design refinements. The Smart Blister-equipped medication cards were generally well received by patients and pharmacies. CONCLUSION: An evaluation of the functionality and robustness of the Smart Blister in a real-world clinical practice situation yielded some promising results, but the findings also indicated a need for design refinements and additional performance testing of the device. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|